Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence ...
Despite the undeniable ability of viral vectors to deliver genetic payloads, and despite the incredible promise of this approach to treat a vast variety of diseases—including metabolic, cardiovascular ...
Adenoviral vectors will transduce a wide range of target cells resulting in high-level gene expression. They are non-integrating vectors so expression in dividing cells is progressively lost. First ...
Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine Newly published research offers a novel technique to ...
SAN FRANCISCO--(BUSINESS WIRE)--64x Bio announced today that they are emerging from stealth and are describing for the first time their proprietary VectorSelect TM platform and vision for the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback